Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An update from Zhaoke Ophthalmology Ltd. ( (HK:6622) ) is now available.
Zhaoke Ophthalmology Limited announced that the National Medical Products Administration of China has accepted its New Drug Application for the CsA Ophthalmic Gel, a treatment for moderate to severe dry eye disease. The gel, which is a proprietary hydrogel formulation, offers improved pharmacokinetic profiles and patient compliance due to its once-daily application and rapid onset of action. This acceptance marks a significant step for the company in enhancing its market position in the ophthalmic industry.
More about Zhaoke Ophthalmology Ltd.
Zhaoke Ophthalmology Limited is a company incorporated in the British Virgin Islands and continued in the Cayman Islands, focusing on the development of innovative ophthalmic products. The company specializes in treatments for eye diseases, with a particular emphasis on products like the CsA Ophthalmic Gel, which targets moderate to severe dry eye disease.
Average Trading Volume: 2,590,007
Technical Sentiment Signal: Buy
Current Market Cap: HK$1.18B
For a thorough assessment of 6622 stock, go to TipRanks’ Stock Analysis page.